Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?

By now, pretty much everyone has heard of Novo Nordisk's (NYSE: NVO) widely popular drug for type 2 diabetes, Ozempic. And, as many investors appreciate, when a pharma company mints a winning product, it's only logical for it to leverage the expertise required to develop the product into making new medicines that are even better.On that note, Novo is already moving very aggressively to invent sequels to Ozempic by flexing its financial might and cutting collaboration agreements with biotechs that might be working on the next big thing. Yet, this doesn't imply that it's using its capital efficiently or that its attempts will succeed.So, let's address the question of whether the stock is worth purchasing in light of its latest investments, as they're doubtlessly a key element of the company's future.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool